Keywords: Shire, Velaglucerase, Gaucher disease

Good Ph III results for Shire’s velaglucerase; FDA accepts rolling NDA

Article | 03 August 2009

Print This

UK drugmaker Shire has reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in